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Abstract
IMPORTANCE National efforts to improve safe opioid prescribing focus on preventing misuse,
overdose, and opioid use disorder. This approach overlooks opportunities to better prevent other
serious opioid-related harms in complex populations, such as older adult survivors of cancer. Little is
known about the rates and risk factors for comprehensive opioid-related harms in this population.
OBJECTIVE To determine rates of multiple opioid-related adverse drug events among older adults
who survived breast cancer and estimate the risk of these events associated with opioid use in the
year after completing cancer treatment.
DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used 2007 to 2016
Surveillance, Epidemiology and End Results-Medicare data from fee-for-service Medicare
beneficiaries with first cancer diagnosis of stage 0 to III breast cancer at age 66 to 90 years from
January 1, 2008, through December 31, 2015, who completed active breast cancer treatment. Data
were analyzed from October 31, 2019, to June 10, 2020.
EXPOSURES Repeated daily measure indicating possession of any prescription opioid supply in
Medicare Part D prescription claims.
MAIN OUTCOMES AND MEASURES Adjusted risk ratios (aRRs), estimated using modified Poisson
generalized estimating equation models, for adverse drug events related to substance misuse (ie,
diagnosed opioid abuse, dependence, or poisoning), other adverse drug events associated with
opioid use (ie, gastrointestinal events, infections, falls and fractures, or cardiovascular events), and
all-cause hospitalization associated with opioid supply the prior day, controlling for patient
characteristics.
RESULTS Among 38 310 women included in the study (mean [SD] age, 74.3 [6.3] years), there were
0.010 (95% CI, 0.008-0.011) adverse drug events related to substance misuse per 1000 person-
days, 0.237 (95% CI, 0.229-0.245) other adverse drug events associated with opioid use per 1000
person-days, and 0.675 (95% CI, 0.662-0.689) all-cause hospitalizations per 1000 person-days.
Opioid use was associated with increased risk of adverse drug events related to substance misuse
(aRR, 14.62; 95% CI, 9.69-22.05; P < .001), other adverse drug events related to opioid use (aRR,
2.50; 95% CI, 2.11-2.96; P < .001), and all-cause hospitalization (aRR, 2.77; 95% CI, 2.55-3.02;
P < .001). In a dose-response effect, individuals with high daily opioid doses had consistently higher
risks of all study outcomes compared with individuals who had low opioid doses. Compared with
days with no opioid exposure, the risk of any adverse drug event related to substance misuse was
3.4-fold higher for individuals with a current opioid supply 50 mg morphine equivalent dose per
day (aRR, 3.40; 95% CI, 2.47-4.68; P < .001), while the risk was 2.3-fold higher for individuals with 1
to 49 mg morphine equivalent dose per day (aRR, 2.29; 95% CI, 1.89-2.77; P < .001).
(continued)
Key Points
Question What are the risks of serious
adverse events associated with
continued prescription opioid use after
completing active treatment for
breast cancer?
Findings In this cohort study among
38 310 older adults who survived breast
cancer, opioid use after active cancer
treatment was associated with a nearly
15-fold increase in immediate risk of
adverse drug events related to
substance misuse, including overdose,
and a 2- to 3-fold increased immediate
risk of other adverse drug events related
to opioid use, such as falls and fractures
or all-cause hospitalization. Other
adverse drug events related to opioid
use were more than 20-fold more
common than events related to
substance misuse.
Meaning These findings suggest that
minimizing unnecessary long-term
opioid therapy after active cancer
treatment may prevent a broad range of
avoidable opioid-related harms,
including those related and unrelated to
substance misuse.
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Abstract (continued)
CONCLUSIONS AND RELEVANCE These findings suggest that among older adults who survived
breast cancer, continued prescription opioid use in the year after completing active cancer treatment
was associated with an immediate increased risk of a broad range of serious adverse drug events
related to substance misuse and other adverse drug events associated with opioid use. Clinicians
should consider the comprehensive risks of managing cancer pain with long-term opioid therapy.
JAMA Network Open. 2020;3(9):e2016858. doi:10.1001/jamanetworkopen.2020.16858
Introduction
The primary focus of opioid policies and prescribing guidelines1 that have emerged in response to the
opioid crisis is to prevent misuse, overdose, and development of opioid use disorder. However,
efforts to reduce unsafe opioid use may also prevent other serious opioid-related adverse drug
events, including gastrointestinal (GI) complications, cardiac events, infection, and falls and fractures
associated with sedation and impaired cognition.2
Preventing serious opioid harms not related to substance misuse may be particularly urgent for
certain at-risk populations, including older adults who have survived cancer. Older adults, who
account for nearly two-thirds of the 16 million people who have survived cancer3 in the US, have high
rates of opioid use4,5 for cancer pain as well as significant clinical complexities owing to their age,6
comorbid conditions,3,7 and cancer treatments. These characteristics may predispose this population
to adverse drug events not related to opioid misuse.
However, little is known about the association between active opioid therapy continuing after
active cancer treatment and comprehensive opioid-related serious adverse drug events. The
purpose of this study was to examine the risk of a broad range of opioid-related serious adverse drug
events among older individuals who survived breast cancer, with the goal of informing tailored opioid
prescribing recommendations for this large, at-risk, and overlooked population.
Methods
Data and Cohort
This retrospective cohort study was approved and determined exempt from informed consent by the
University of Kansas Medical Center institutional review board because data were deidentified and
study investigators had no direct or indirect access to personally identifiable information. We
adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline for observational cohort studies. The study used Surveillance, Epidemiology and
End Results-Medicare data for 2007 to 2016 to estimate the immediate risk of opioid-related adverse
drug events associated with time-dependent daily opioid exposure in the year after active breast cancer
treatment. We focused on this period to examine harms from potentially avoidable long-term opioid
therapy extending beyond the active cancer treatment phase.8 We defined the end of active cancer
treatment as the last day following the breast cancer diagnosis date on which an individual was recorded
as receiving chemotherapy, radiation, or curative surgical cancer treatment.9
We evaluated women aged 66 to 90 years diagnosed with Surveillance, Epidemiology and End
Results-confirmed stage 0 to III breast cancer from January 1, 2008, to December 31, 2015, who did
not have a previous cancer diagnosis. We required women to have continuous Medicare Parts A and
B coverage from 12 months before their breast cancer diagnosis through 12 months after the end of
active breast cancer treatment; we also required women to have Medicare Part D coverage from 3
months before diagnosis through 12 months after the end of active breast cancer treatment. We
excluded individuals who died or recorded a second primary cancer diagnosis during the 12 months
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of follow-up after diagnosis; did not have a full 12 months of follow-up before December 31, 2016; or
had any prior opioid prescription filled in the 3 months before diagnosis.
Measures
Outcome measures included time-dependent daily binary measures indicating whether an individual
experienced a serious opioid-related adverse drug event on a given day during the 12-month
follow-up period after the individual had completed active cancer treatment. Opioid-related adverse
drug events consisted of those related to substance misuse (ie, diagnosed opioid dependence,
abuse, or poisoning)10 and those unrelated to substance misuse or opioids’ abuse or overdose
potential (ie, serious infection,11 GI events,12 falls and fractures,12 cardiovascular events,12 and
all-cause hospitalization) (eFigure in the Supplement). Days when an individual was hospitalized
were excluded from analyses.
The primary independent variable was a time-dependent binary measure indicating exposure
vs no exposure to prescription opioids on each day across the 12-month follow-up period, using Part
D prescription fill data. Time-invariant covariates included cancer diagnosis, treatment
characteristics, and additional patient demographic and clinical characteristics measured during the
12-month baseline period before cancer diagnosis.
Statistical Analysis
Descriptive statistics reported outcome, demographic, clinical, and treatment characteristics for the
cohort. We estimated the unadjusted rate of each outcome event per 1000 person-days in the year
after active breast cancer treatment. We leveraged our time-dependent daily outcome and exposure
measures using modified Poisson generalized estimating equations13 to estimate adjusted risk ratios
(aRRs) for all adverse drug event outcomes associated with opioid exposure on the preceding day
compared with no opioid exposure on the previous day. We lagged opioid exposure by 1 day to
protect against erroneous conclusions related to reverse causation. Generalized estimating
equations did not converge for the substance misuse–related event outcome, so we accounted for
repeated daily observations for this outcome by clustering SEs within individuals. We adjusted for
time-invariant patient demographic, clinical, cancer diagnosis, and cancer treatment characteristics.
The data were analyzed from October 31, 2019, to June 10, 2020. All analyses were performed
using 2-sided hypothesis tests in Stata statistical software version 16 (StataCorp), and significance
was assumed as P < .05.
We conducted sensitivity analyses to assess for a dose-response association between the
intensity of an individual’s current opioid exposure and risk of a serious opioid-related adverse drug
event. In this analysis, we characterized daily opioid exposure measures as high (50 mg morphine
equivalent dose [MED] per day), low (1-49 mg MED per day), or none.14 We also measured opioid
exposure intensity as a rolling mean of daily milligrams of MED over the previous 14 days,
dichotomized as high vs low opioid exposure.
Results
We analyzed a cohort of 38 310 older women with mean (SD) age 74.3 (6.3) years (Table 1). There
were 0.010 (95% CI, 0.008-0.011) adverse drug events related to substance misuse per 1000
person-days, 0.237 (95% CI, 0.229-0.245) other adverse drug events associated with opioid use per
1000 person-days, and 0.675 (95% CI, 0.662-0.689) all-cause hospitalizations per 1000 person-
days (Table 2). Other adverse drug events associated with opioid use were 23.7-fold more common
than adverse drug events related to opioid misuse. Our adjusted analysis showed a consistent
positive association between current opioid exposure and serious adverse drug events (Figure).
Compared with days without opioid exposure, current opioid exposure was associated with 2.5-fold
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higher risk of a serious adverse drug event not related to substance misuse (aRR, 2.50; 95% CI, 2.11-
2.96; P < .001) and nearly 3-fold the immediate risk of all-cause hospitalization (aRR, 2.77; 95%, CI,
2.55-3.02; P < .001).
Opioid exposure was also associated with higher immediate risk of an adverse drug event
related to substance misuse (aRR, 14.62; 95% CI, 9.69-22.05; P < .001). Among specific other serious
adverse drug events related to opioid use, current opioid exposure was associated with increased
risk of GI events (aRR, 2.87; 95% CI, 1.95-4.24; P < .001), falls and fractures (aRR, 2.34; 95% CI, 1.69-
3.25; P < .001), cardiovascular events (aRR, 2.38; 95% CI, 1.80-3.16; P < .001), and serious infections
(aRR, 3.26; 95% CI, 2.59-4.10; P < .001). In sensitivity analyses, we found a consistent dose-response
Table 1. Patient Characteristics
Characteristic No. (%) (N = 38 310)
Age, y
Mean (SD) 74.7 (6.3)
66-70 12 231 (31.9)









Low-income subsidy 7752 (20.2)
Charlson comorbidity score
0 20 332 (53.1)








≤2 25 337 (66.2)






Partial 22 773 (59.4)
Lymph node surgical treatment 1145 (3.0)
Tumor biopsy 1525 (4.0)
None 198 (0.5)
Hormonal therapy 11 312 (29.5)
Radiation 20 720 (54.1)
Adjuvant chemotherapy 5228 (13.7)
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association between opioid exposure intensity and serious adverse drug events (eFigure in the
Supplement). For example, compared with days with no opioid exposure, the risk of any adverse
drug event related to substance misuse was 3.4-fold higher for individuals with a current opioid
supply 50 mg MED per day (aRR, 3.40; 95% CI, 2.47-4.68; P < .001), while the risk was 2.3-fold
higher for individuals with 1 to 49 mg MED per day (aRR, 2.29; 95% CI, 1.89-2.77; P < .001).
Discussion
In this cohort study of older adults who survived breast cancer, we found that individuals with
current opioid exposure, especially high-dose opioid exposure, on a given day in the year after active
breast cancer treatment had significantly higher immediate adjusted risk of myriad serious adverse
drug events compared with their risk on days without opioid exposure. Notably, the risks of GI
events, infection, falls and fractures, and cardiovascular events were 2- to 3-fold higher on days with
current opioid exposure. These serious adverse drug events were also more than 20-fold more
common than events related to substance misuse, such as opioid overdose. As efforts to increase
opioid safety for treating cancer pain increase, it is important for clinicians to recognize that opioid-
related risks in this population extend beyond misuse, overdose, and opioid use disorder.
Table 2. Unadjusted Outcome Event Rates per 1000 Patient-Days
Outcome
No.








Days at risk 13 666 612 NA 373 272 NA 13 293 340 NA
Substance misuse–related ADEa 130 0.010 (0.008-0.011) 45 0.121 (0.085-0.156) 85 0.006 (0.005-0.008)
Other opioid use–associated ADEb 3242 0.237 (0.229-0.245) 328 0.879 (0.784-0.974) 2914 0.219 (0.211-0.227)
GI event 322 0.024 (0.021-0.026) 31 0.083 (0.054-0.112) 291 0.022 (0.019-0.024)
Fall or fracture 1329 0.097 (0.092-0.103) 133 0.356 (0.296-0.417) 1196 0.090 (0.085-0.095)
Cardiovascular event 710 0.052 (0.048-0.056) 63 0.169 (0.127-0.211) 647 0.049 (0.045-0.052)
Serious infection 927 0.068 (0.064-0.072) 106 0.284 (0.230-0.338) 821 0.062 (0.058-0.066)
All-cause hospitalization 9228 0.675 (0.662-0.689) 953 2.553 (2.391-2.715) 8275 0.623 (0.609-0.636)
Abbreviations: ADE, adverse drug event; GI, gastrointestinal; NA, not applicable.
a Includes diagnosed opioid abuse, dependence, and poisoning.
b May be smaller than the separate total number of events if an individual is diagnosed
with more than 1 adverse drug event during a single health care encounter.
Figure. Adverse Drug Events (ADEs) Associated With Current Opioid Use vs No Current Opioid Use After Breast Cancer Treatment
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Point estimates (boxes) and 95% CIs (whiskers) were estimated using modified Poisson
generalized estimating equations for the association between any current opioid
exposure vs no current opioid exposure on ADE outcomes in the year after completing
active breast cancer treatment. The substance misuse–related ADE model was estimated
using modified Poisson clustering on individual because of lack of convergence in
generalized estimating equations. Estimates adjusted for age, race/ethnicity (ie, White,
Black, Hispanic, or other), low-income subsidy receipt, comorbidity score (ie, 0, 1, or 2),
cancer stage (ie, 0, I, II, or III), tumor size (ie, 2 cm, <2 to <5 cm, 5 cm, or unknown
size), breast surgical treatment (ie, mastectomy, partial mastectomy, lymph node
surgery, tumor biopsy, or none), use of hormonal therapy, use of radiation, use of
adjuvant chemotherapy, use of any chemotherapy, any use of trastuzumab, any use of a
taxane, and any use of doxorubicin. Vertical dotted line indicates reference null adjusted
risk ratio of 1.00.
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Limitations
This study has some limitations. First, prescription fill records in claims data do not equate to use.
Second, we examined a 1-day lag in association between opioid supply and adverse drug events, so
as not to exclude individuals hospitalized for an adverse drug event. Because of this, we could not
assess instances in which individuals received new opioid therapy earlier in the same day that they
recorded an adverse drug event. Third, opioids are often used as needed, meaning individuals may
use the medications beyond the period accounted for by the days’ supply in the Part D claim. Our
sensitivity analysis used a 14-day rolling mean and produced similar results to analyzing the minimum
day’s amount. Fourth, this study may include confounding by indication, in which individuals with
more severe symptoms receive more opioid therapy. We believe that a broad outcome, such as
all-cause hospitalization, may be subject to this bias, but the adverse drug events related to
substance misuse and other adverse drug events related to opioid use (eg, GI or cardiovascular
events) are less likely to have such a bias. Fifth, our findings may not generalize to other cancers or
younger populations.
Conclusions
Opioids remain a mainstay of cancer pain management; however, increasing evidence indicates that
the benefits of long-term opioid use for cancer pain may be limited.15 Our findings add to these
concerns by demonstrating that opioid therapy significantly increases the risk of multiple
preventable serious adverse drug events. Clinicians should carefully weigh the benefits and
comprehensive risks of opioid therapy in older adult survivors of breast cancer who have completed
active breast cancer treatment.
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